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Abstract
Background: Drug resistance is an emerging problem among streptococcal and enterococcal
species. Automated diagnostic systems for species identification and antimicrobial susceptibility
testing (AST) have become recently available. We evaluated drug susceptibility of clinical isolates
of streptococci and enterococci using the recent Phoenix system (BD, Sparks, MD). Diagnostic
tools included the new SMIC/ID-2 panel for streptococci, and the PMIC/ID-14 for enterococci.
Two-hundred and fifty isolates have been investigated: β-hemolytic streptococci (n = 65),
Streptococcus pneumoniae (n = 50), viridans group streptococci (n = 32), Enterococcus faecium (n =
40), Enterococcus faecalis (n = 43), other catalase-negative cocci (n = 20). When needed, species ID
was determined using molecular methods. Test bacterial strains were chosen among those carrying
clinically-relevant resistance determinants (penicillin, macrolides, fluoroquinolones, glycopeptides).
AST results of the Phoenix system were compared to minimal inhibitory concentration (MIC)
values measured by the Etest method (AB Biodisk, Solna, Sweden).
Results: Streptococci: essential agreement (EA) and categorical agreement (CA) were 91.9% and
98.8%, respectively. Major (ME) and minor errors (mE) accounted for 0.1% and 1.1% of isolates,
respectively. No very major errors (VME) were produced. Enterococci: EA was 97%, CA 96%.
Small numbers of VME (0.9%), ME (1.4%) and mE (2.8%) were obtained. Overall, EA and CA rates
for most drugs were above 90% for both genera. A few VME were found: a) teicoplanin and high-
level streptomycin for E. faecalis, b) high-level gentamicin for E. faecium. The mean time to results
(± SD) was 11.8 ± 0.9 h, with minor differences between streptococci and enterococci.
Conclusion: The Phoenix system emerged as an effective tool for quantitative AST. Panels based
on dilution tests provided rapid and accurate MIC values with regard to clinically-relevant
streptococcal and enterococcal species.
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Background
Resistance of streptococci and enterococci to different
classes of antimicrobials is increasing worldwide [1,2].
Reduced susceptibility or resistance to penicillin and
other β-lactams have been reported with particular fre-
quency in the case of Streptococcus pneumoniae and viri-
dans streptococci [1,3]. Resistance to macrolides and
fluoroquinolones has been described in viridans and β-
hemolytic streptococci [4,5]. Notably, glycopeptide resist-
ance is an increasing threat among enterococcal species,
especially Enterococcus faecium and E. faecalis [2].
Since clinical isolates of all the above species may produce
severe infections (sepsis, meningitis, endocarditis), rapid
and accurate identification (ID) and antimicrobial suscep-
tibility testing (AST) are of great significance. For these
bacteria, evaluation of drug susceptibility using disk diffu-
sion methods can be problematic since the technique
does not provide quantitative values. In this context, the
Clinical Laboratory Standards Institute (CLSI; formerly
NCCLS) established that S. pneumoniae isolates should
not be reported as penicillin-resistant or intermediate
based solely on an oxacillin zone ≤ 19 mm [6]. For these
strains, minimum inhibitory concentration (MIC) values
of penicillin and cefotaxime/ceftriaxone or meropenem
are mandatory. Correct detection of vancomycin resist-
ance among enterococci is also critical, since diffusion is
difficult for large molecules and interpretative criteria are
based on limited differences in the inhibition zone. MIC
values may be of further assistance in discriminating ente-
rococcal species carrying different van-type determinants.
Reproducibility of results, accuracy of species ID, preci-
sion of quantitative AST results, turnaround time, availa-
bility of data for epidemiological monitoring, and cost-
effectiveness represent compelling reasons that support
the choice of an automated system for clinical bacteriol-
ogy. Systems of this type are now available for catalase-
negative gram-positive cocci [7-9]. In the year 2000, Bec-
ton Dickinson (BD Diagnostic Systems, Sparks, MD)
introduced the Phoenix Automated Microbiology System
for ID and AST of gram-negative bacilli, staphylococci,
and enterococci [10-13]. More recently, a panel for strep-
tococcal species (SMIC/ID-2 panel) has been added
[14,15].
The present study was designed to evaluate the perform-
ance of the Phoenix system for the quantitative determi-
nation of drug susceptibility of streptococcal and
enterococcal isolates carrying different resistance determi-
nants. Time to results was also analyzed.
Results
Bacterial isolates are listed in Table 1. AST results are
expressed as raw data (i.e., as results not interpreted by the
expert system). For streptococcal isolates (Table 2), the
overall essential agreement (EA; 91.9%) and categorical
agreement (CA; 98.8%) between the Phoenix system and
the Etest method were satisfactory. No VME were pro-
duced. Very low rates of major errors (ME; 0.1%) and
minor errors (mE; 1.1%) were found. For enterococcal
isolates (Table 3), the overall EA and CA were 97% and
96%, respectively. Small numbers of errors were found:
VME (0.9%), ME (1.4%), mE (2.8%).
As shown in Tables 2 and 3, the overall performance for
different antimicrobials was rather satisfactory (mean EA
for streptococci ≥ 91%, for enterococci ≥ 97%). Poor per-
formances were, however, noticed for streptococci in the
case of clindamycin (EA, 67.3%) and erythromycin (EA,
88.6%), and for enterococci in the case of teicoplanin (EA,
87%). CA rates ≥ 97% and ≥ 94% were obtained for strep-
tococci and enterococci, respectively. However, the low
CA rate obtained in the case of linezolid for enterococci
(89%) should be noticed.
Table 1: Streptococcal and enterococcal isolates investigated in 
the study.
Organism No. isolates
Streptococci (n = 150)
Streptococcus pneumoniae 50
Beta-hemolytic streptococci (n = 65)
Streptococcus pyogenes 20
Streptococcus agalactiae 20
Streptococcus dysgalactiae subsp. equisimilis 25
S. bovis 3
Viridans streptococci (n = 32)













Enterococci (n = 100)
Enterococcus faecalis 43
Enterococcus faecium 40





Total 250BMC Microbiology 2007, 7:46 http://www.biomedcentral.com/1471-2180/7/46
Page 3 of 7
(page number not for citation purposes)
Table 4 shows the AST results relative to different species
or groups of streptococci. Mean CA values were as follows:
S. pneumoniae 95%, β-hemolytic-streptococci 99.4%, and
viridans streptococci 99.6%. With regard to beta-lactams,
mE have been obtained only with S. pneumoniae: penicil-
lin (12%), cefotaxime (2%), and cefepime (2%). Among
S. pyogenes isolates, one ME for clindamycin was observed.
As shown in Table 5, rather satisfactory CA values were
obtained with E. faecalis (98.2%) and E. faecium (96.7%).
Occasional VME have been produced for teicoplanin and
HL-streptomycin in E. faecalis, and for HL-gentamicin in
E. faecium. Due to the reduced numbers, results of isolates
belonging to species other than E. faecalis and E. faecium
(see Table 1) are not presented in Table 5. For these spe-
cies, mean CA value was 88.9%; mE and ME were 7.2%
and 5.3%, respectively. Errors were restricted to chloram-
phenicol, tetracycline, linezolid, and quinupristin-dalfo-
pristin.
Time to results (TTR)
TTR values represent the overall time required for both ID
and AST results. The mean TTR ± SD was 11.8 ± 0.9 h, with
minor differences between streptococci (12.4 ± 2.2) and
enterococci (11.4 ± 3.0). Among streptococci, β-hemo-
lytic species showed the lowest TTR (S. agalactiae, 11.3 h;
S. pyogenes, 11.6 h; S. dysgalactiae, 11.7 h). S. pneumoniae
and viridans group streptococci were characterized by
longer TTR (13.1 h and 13.3 h, respectively). Among ente-
rococci, TTR was 9.9 ± 2.8 h for E. faecalis, and 11.7 ± 2.3
h for E. faecium.
Discussion
Over 70 streptococcal and enterococcal species have been
implicated in animal and/or human infections [16,17].
Of these, only a few cause important human infections
(e.g., S. pyogenes, S. pneumoniae, S. agalactiae, E. faecalis, E.
faecium, viridans streptococci).
Streptococcal and enterococcal isolates characterized by a
wide spectrum of drug susceptibility have been investi-
gated to assess the performance of the Phoenix system
using both the new SMIC/ID-2 panel for streptococci and
the established PMIC/ID-14 panel for enterococci. Both
panels allowed testing clinically-relevant drugs: penicil-
Table 3: Enterococci: overall agreement of AST results between the Phoenix system and the Etest method.
Antibiotic Susceptibility (No.) Essential agreement Categorical 
agreement
Minor errors Major errors Very major errors
S I R % % No. (%) No. (%) No. (%)
Ampicillin 62 0 38 100 100 0 0 0
Vancomycin 59 10 31 97.0 96.0 4 (4.0) 0 0
Teicoplanin 73 3 24 87.0 94.0 3 (3.0) 2 (2.7) 1 (4.2)
HL streptomycin 47 0 53 99.0 99.0 0 0 1 (1.9)
HL gentamicin 53 0 47 99.0 99.0 0 0 1 (2.1)
Chloramphenicol 81 3 16 95.0 94.0 2 (2.0) 4 (4.9) 0
Linezolid 100 0 0 97.0 89.0 10 (10.0) 1 (1.0) 0
Quinupristin-dalfopristin 36 9 55 100 94.0 6 (6.0) 0 0
Tetracycline 50 1 49 99.0 99.0 0 1 (2.0) 0
Total 561 26 313 97.0 96.0 25 (2.8) 8 (1.4) 3 (0.9)
Table 2: Streptococci: overall agreement of AST results between the Phoenix system and the Etest method.
Antibiotic Susceptibility (No.) Essential agreement Categorical agreement Minor errors Major errors Very major errors
S I R % % No. (%) No. (%) No.
Penicillin 126 19 5 93.3 96.0 6 (4.0) 0 0
Erythromycin 95 0 55 88.6 100 0 0 0
Clindamycin 108 2 40 67.3 97.3 3 (2.0) 1 (0.9) 0
Levofloxacin 133 0 17 90.7 99.3 1 (0.7) 0 0
Chloramphenicol 139 0 11 97.3 99.3 1 (0.7) 0 0
Cefotaxime 149 0 1 98.0 99.3 1 (0.7) 0 0
Cefepime 145 4 1 100 99.3 1 (0.7) 0 0
Vancomycin 150 0 0 100 100 0 0 0
Total 1,045 25 130 91.9 98.8 13 (1.1) 1 (0.1) 0BMC Microbiology 2007, 7:46 http://www.biomedcentral.com/1471-2180/7/46
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lins, third- and fourth-generation cephalosporins, mac-
rolides, fluoroquinolones, glycopeptides, and the newer
molecules linezolid and quinupristin-dalfopristin.
The results demonstrate the overall satisfactory perform-
ance of the Phoenix system. CA and EA values were con-
sistently > 90% (98.8% and 91.9%, for streptococci; 96%
and 97%, for enterococci). The lowest CA values were
obtained with S. pneumoniae and with enterococci other
than E. faecalis and E. faecium.
For streptococci, results in agreement with ours have been
obtained by Japanese investigators [14,15] that used
SMIC/ID panels differing from those used by us. As com-
pared to the automated Vitek system, the Phoenix
appeared more accurate in determining MIC values for
pneumococci [18]. Excellent results were obtained with
both systems with regard to S. agalactiae [9]. Among ente-
rococci, our results showed lower performances with
respect to what has been reported by others using both the
Phoenix and the Vitek systems [9,12,19]. In this respect, it
should be noted that a high proportion (46/100) of our
isolates carried glycopeptide resistance determinants and
that 17/100 isolates were of species other than E. faecalis
and E. faecium. Problems with AST results for the above
species have also been reported by others using auto-
mated systems [20].
Unsatisfactory results have been obtained for clindamycin
in the case of streptococci (EA, 67.3%): MIC values pro-
duced by the Phoenix were, in fact, usually lower than
those obtained with the Etest. Investigated strains, how-
ever, showed MICs consistently within breakpoint values,
thus limiting the clinical impact of the error. The reduced
Table 5: Agreement of AST results produced by the Phoenix system and the Etest method: E. faecalis and E. faecium.
Antibiotic % of corresponding results
E. faecalis (n = 43) E. faecium (n = 40)
CA mE ME VME CA mE ME VME
Ampicillin 100 0 0 0 100 0 0 0
Vancomycin 97.7 2.3 0 0 92.5 7.5 0 0
Teicoplanin 97.7 0 0 16.7 87.5 7.5 5.7 0
HL streptomycin 97.7 0 0 6.7 100 0 0 0
HL gentamicin 100 0 0 0 97.5 0 0 4.0
Chloramphenicol 100 0 0 0 97.5 2.5 0 0
Linezolid 90.7 9.3 0 0 97.5 2.5 0 0
Quinupristin-dalfopristin 100 0 0 0 100 0 0 0
Tetracycline 100 0 0 0 100 0 0 0
Total 98.2 1.3 0 1.4 96.7 2.5 1.0 0.7
Table 4: Agreement of AST results produced by the Phoenix system and the Etest method: streptococci of different species or 
groups.
Antibiotic % of corresponding results
S. pneumoniae (n = 50) Beta-hemolytic streptococci (n = 65) Viridans group streptococci (n = 32)
CA mE ME VME CA mE ME VME CA mE ME VME
Penicillin 88.0 12.0 0 0 100 0 0 0 100 0 0 0
Erythromycin 100 0 0 0 100 0 0 0 100 0 0 0
Clindamycin 96.0 4.0 0 0 98.5 0 1.7 0 96.9 3.1 0 0
Levofloxacin 100 0 0 0 98.5 1.5 0 0 100 0 0 0
Chloramphenicol 100 0 0 0 98.5 1.5 0 0 100 0 0 0
Cefotaxime 98.0 2.0 0 0 100 0 0 0 100 0 0 0
Cefepime 98.0 2.0 0 0 100 0 0 0 100 0 0 0
Vancomycin 100 0 0 0 100 0 0 0 100 0 0 0
Total 95.0 5.0 0 0 99.4 0.4 0.2 0 99.6 0.4 0 0BMC Microbiology 2007, 7:46 http://www.biomedcentral.com/1471-2180/7/46
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response to clindamycin was not related to the expression
of resistance determinants (inducible/constitutive MLSB
phenotype, or efflux; data not shown). Overall, small
numbers of VME and ME were obtained. Most errors were
classified as mE, due to minor differences in MIC values
around breakpoint concentrations. Regarding ten entero-
coccal isolates, the Phoenix system gave MIC values of 4
µg/ml for linezolid, thus classifying the isolates as "inter-
mediate". MIC values given by the Etest were instead of 2
µg/ml (i.e., "susceptible"). The finding appears to reflect a
problem already noticed by Phoenix users with regard to
this drug. Thus, increased linezolid MICs need to be veri-
fied using a reference method. Regarding penicillin, mE
were encountered in 6/150 streptococci. In the latter
cases, MICs were overestimated by the Phoenix system.
Overall, the results of the present study were superior to
those previously reported for both the Phoenix and the
VITEK 2 system [14,15,18].
A mE rate < 10% is recommended for accepting AST
results, and up to 3.0% ME and 1.5% VME are acceptable
[21]. Overall, the results produced by the Phoenix were
well within the recommended range. However, an ME rate
of 5.3% was obtained for enterococci other than E. fae-
cium and E. faecalis.
Conclusion
The Phoenix system appears an effective diagnostic tool
for infections caused by streptococci and enterococci. Pan-
els based on dilution tests were able to deliver adequate
quantitative AST results in short times. This is especially
relevant for severe infections caused by aggressive species
such as S. pyogenes, S. pneumoniae, E. faecalis, and E. fae-
cium. For these organisms, interpretation of susceptibility
data varies according to the infection site and – in the case
of large molecules that hardly diffuse in solid media (e.g.,
glycopeptides) – results obtained using dilution methods
are to be preferred [20,22].
Methods
Clinical isolates
Bacterial strains were obtained from routine clinical spec-
imens at the Microbiology Laboratory of the Ospedale di
Circolo, Varese (Italy). A total of 250 non-duplicate clini-
cal isolates of gram-positive, catalase-negative cocci were
studied. When needed, species ID was obtained by molec-
ular methods [23]. The following species were investi-
gated (Table 1): S. pneumoniae,  Streptococcus pyogenes,
Streptococcus agalactiae,  Streptococcus dysgalactiae subsp.
equisimilis, viridans group streptococci, E. faecium, E. faec-
alis, plus other streptococcal and enterococcal species. Test
organisms included isolates characterized by different sus-
ceptibility levels to penicillin, macrolides, and fluoroqui-
nolones. Among enterococci (n = 100), vancomycin
resistance determinants were present in 46 isolates: vanA
(33 isolates), vanB (2 isolates), vanC1 (7 isolates), and
vanC2 (4 isolates). Fifty-four vancomycin-susceptible iso-
lates were shown not to carry van-type determinants. Glyc-
opeptide-resistance determinants (vanA,  vanB,  vanC-1,
vanC-2, van-C-3, vanD, vanE, and vanG) were investigated
by PCR following reported methods [24]. Isolates were
stored at -70°C in Todd-Hewitt broth containing 20%
glycerol. Before performing ID and AST assays, the isolates
were passed twice on Mueller-Hinton agar containing 5%
sheep blood (Oxoid SpA, Milan, Italy) to get them to an
active growth stage following metabolic inactivity while
frozen.
Phoenix AST
The Phoenix system uses two different panels for ID and
AST of gram-positive cocci: the SMIC/ID-2 panel for strep-
tococci, and the PMIC/ID-14 panel for enterococci and
staphylococci. Panels have two separate sections. The left
one contains ID substrates. The AST section (right side)
contains three to eight concentrations of different drugs.
Panel inoculation has been performed according to the
manufacturer's instructions. As recommended, the same
ID broth has been used for both panel types. Two different
broth types are instead needed for AST. The AST-S broth
containing growth supplements plus one drop of the
Phoenix AST-S indicator is intended for streptococci. The
AST broth plus one drop of the Phoenix AST indicator is
intended for enterococci, staphylococci, and gram-nega-
tive bacteria.
Bacterial isolates have been obtained from fresh overnight
cultures, suspended in the ID broth and adjusted to the
0.5 McFarland standard using a dedicated nephelometer
(CrystalSpec, BD). Twenty-five microliters of the ID sus-
pension have been used to inoculate AST broths, resulting
in the final inoculum density of approximately 5 × 105
CFU/ml. Inoculated AST broths have been poured into
the appropriate sections of each panel. Panels have been
sealed, logged, and loaded into the instrument at 35°C.
Kinetic, colorimetric and fluorescent signals have been
collected every 20 min until ID and AST results were com-
pleted.
Comparator AST method
MICs have been determined by the Etest method (AB Bio-
disk, Solna, Sweden) according to manufacturer's instruc-
tions (preparation of inoculum, plating, strip application,
reading of results). Streptococcal isolates have been cul-
tured on Mueller-Hinton agar plates supplemented with
5% sheep blood (Oxoid). Enterococcal isolates have been
tested on Mueller-Hinton agar plates (BD). Vancomycin
has been tested on brain heart infusion plates (Oxoid).
MIC values have been interpreted according to CLSI crite-
ria [6]. Different drug panels have been tested for strepto-
cocci and enterococci: a) streptococci (penicillin,BMC Microbiology 2007, 7:46 http://www.biomedcentral.com/1471-2180/7/46
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erythromycin, clindamycin, cefotaxime, cefepime, levo-
floxacin, vancomycin, chloramphenicol); b) enterococci
[ampicillin, vancomycin, teicoplanin, high-level (HL)
streptomycin, HL gentamicin, chloramphenicol, quinu-
pristin-dalfopristin, tetracycline, linezolid].
Analysis of data and discrepancies
AST results are reported as raw data, i.e. without interpre-
tation by the expert system. Results have been categorized
as susceptible (S), intermediate (I), or resistant (R)
according to CLSI [6]. MIC values produced by the Phoe-
nix method (TEST) have been compared to those
obtained with the Etest method (COMP). The following
definitions have been adopted: 1) EA (i.e., MIC values of
TEST panel equal to or within ± 1 dilution of the COMP
value); 2) CA (i.e., TEST and COMP MIC values agree
using insterpretative CLSI criteria); 3) mE (i.e., COMP is S
or R and TEST is I; alternatively, COMP is I and TEST is S
or R); 4) ME (i.e., COMP is S and TEST is R; the percentage
of major errors has been calculated only for susceptible
isolates); 5) VME (i.e., COMP is R and TEST is S; the per-
centage of very major errors has been calculated only for
resistant isolates). In the case of ME or VME, the organism
has been re-tested with both the Phoenix and the Etest.
When differences persisted, the results have been consid-
ered discordant.
Quality controls
As controls, the following strains have been included in
each run: S. pneumoniae ATCC 49619, S. agalactiae ATCC
13813, and E. faecalis ATCC 29212.
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